Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 584
Filtrar
1.
Int J Mol Sci ; 25(11)2024 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-38892036

RESUMEN

The extracellular matrix is a complex network of proteins and other molecules that are essential for the support, integrity, and structure of cells and tissues within the human body. The genes ZNF469 and PRDM5 each produce extracellular-matrix-related proteins that, when mutated, have been shown to result in the development of brittle cornea syndrome. This dysfunction results from aberrant protein function resulting in extracellular matrix disruption. Our group recently identified and published the first known associations between variants in these genes and aortic/arterial aneurysms and dissection diseases. This paper delineates the proposed effects of mutated ZNF469 and PRDM5 on various essential extracellular matrix components, including various collagens, TGF-B, clusterin, thrombospondin, and HAPLN-1, and reviews our recent reports associating single-nucleotide variants to these genes' development of aneurysmal and dissection diseases.


Asunto(s)
Matriz Extracelular , Factores de Transcripción , Humanos , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Matriz Extracelular/metabolismo , Matriz Extracelular/genética , Inestabilidad de la Articulación/genética , Inestabilidad de la Articulación/congénito , N-Metiltransferasa de Histona-Lisina/genética , Distrofias Hereditarias de la Córnea/genética , Distrofias Hereditarias de la Córnea/patología , Síndrome de Ehlers-Danlos/genética , Síndrome de Ehlers-Danlos/patología , Aneurisma de la Aorta/genética , Mutación , Proteínas de Unión al ADN/genética , Enfermedades Cutáneas Genéticas/genética , Enfermedades Cutáneas Genéticas/patología , Predisposición Genética a la Enfermedad , Polimorfismo de Nucleótido Simple , Anomalías del Ojo , Anomalías Cutáneas
2.
Arch Dermatol Res ; 316(6): 333, 2024 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-38844593

RESUMEN

BACKGROUND: Stiff skin syndrome (SSS) is a rare disease characterized by thickened, indurated skin and limited joint movement. Multiple diverse phenotypes have been reported, and the correlation of severity with the clinical heterogeneity and histopathological findings of SSS needs to be refined. OBJECTIVE: To define subtypes based on clinical features and predict the prognosis of a new SSS classification. METHODS: Eighty-three patients with SSS were retrospectively reviewed for clinicopathological manifestations and routine laboratory workup, including 59 cases obtained from a PubMed search between 1971 and 2022 and 24 cases diagnosed in our department between 2003 and 2022. RESULTS: Among the 83 patients, 27.7, 41, and 31.3% had classic widespread, generalized segmental, and localized SSS, respectively. Joint immobility was present in 100, 71, and 20% of classic, generalized, and localized cases, respectively. Histopathologic findings were common among the 3 groups, and based on that, we further found a difference in the distribution of proliferative collagen. 54.5% of classic and 50% of generalized cases occurred throughout the dermis or the subcutis, whereas 76% of localized cases were mainly involved in the reticular dermis or subcutis. In patients with incipient localized SSS, 42% (21/50) developed generalized SSS, and only 6% (3/50) progressed to classic SSS, whereas more than half of the incipient generalized SSS cases (60.6%, 20/33) developed classic SSS. LIMITATIONS: This retrospective study was limited to previously published cases with limited data. CONCLUSIONS: We propose a distinct clinical classification characterized by lesion distribution, including classic widespread, generalized segmental, and localized SSS, associated with disease severity and prognosis.


Asunto(s)
Piel , Humanos , Femenino , Masculino , Estudios Retrospectivos , Adulto , Persona de Mediana Edad , Adolescente , Piel/patología , Adulto Joven , Niño , Pronóstico , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/clasificación , Enfermedades Cutáneas Genéticas/patología , Anciano , Índice de Severidad de la Enfermedad , Preescolar , Colágeno/metabolismo , Contractura
3.
Arch Dermatol Res ; 316(6): 282, 2024 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-38796611

RESUMEN

Skin cancers are associated with a large number of genodermatoses. Existing knowledge and guidelines on the presentations of these genodermatoses focus disproportionately on White patients. Our goal is to identify notable characteristics in location, frequency, and severity of cutaneous findings along with the median age of skin cancers in skin-of-color (SOC) patients with skin-cancer-associated genodermatoses to improve diagnosis rates. We searched for genodermatoses on six databases. Each case report or case series was reviewed, including reports, published in English, containing adult patient descriptions. Duplicate manuscripts were removed using EndNote. The following case-level data were collected from the manuscripts: age, gender, patient country or region of origin, author country/continent of residence, skin cancer-related, and other key dermatologic features. 381 published articles, with a total of 578 SOC patients, met criteria for inclusion. SOC patients can present with fewer classic findings, such as a lower incidence of basal cell carcinomas (44%) in SOC Gorlin syndrome patients than palmar pits (66%) and mandibular cysts (66%). Differences between SOC populations were also noted, such as leukoplakia being more common in Asian dyskeratosis congenita patients (80%) in comparison to African dyskeratosis congenita patients (44%). SOC patients also have varying onset of skin cancer depending on the genodermatosis, from a median of 25 years of age in Rothmund-Thomson syndrome to 53 in Muir-Torre syndrome. In this review, SOC patients with genodermatoses can have varying presentations. Being cognizant of these characteristics may lead to earlier diagnosis and interventions to mitigate skin-cancer-related morbidity in SOC patients.


Asunto(s)
Neoplasias Cutáneas , Femenino , Humanos , Masculino , Carcinoma Basocelular/epidemiología , Carcinoma Basocelular/patología , Carcinoma Basocelular/diagnóstico , Piel/patología , Enfermedades Cutáneas Genéticas/epidemiología , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/patología , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Minorías Étnicas y Raciales
5.
J Pediatr Endocrinol Metab ; 37(5): 467-471, 2024 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-38529810

RESUMEN

OBJECTIVES: Inactivating GNAS mutations result in varied phenotypes depending on parental origin. Maternally inherited mutations typically lead to hormone resistance and Albright's hereditary osteodystrophy (AHO), characterised by short stature, round facies, brachydactyly and subcutaneous ossifications. Paternal inheritance presents with features of AHO or ectopic ossification without hormone resistance. This report describes the case of a child with osteoma cutis and medulloblastoma. The objective of this report is to highlight the emerging association between inactivating germline GNAS mutations and medulloblastoma, aiming to shed light on its implications for tumor biology and promote future development of targeted surveillance strategies to improve outcomes in paediatric patients with these mutations. CASE PRESENTATION: A 12-month-old boy presented with multiple plaque-like skin lesions. Biopsy confirmed osteoma cutis, prompting genetic testing which confirmed a heterozygous inactivating GNAS mutation. At 2.5 years of age, he developed neurological symptoms and was diagnosed with a desmoplastic nodular medulloblastoma, SHH molecular group, confirmed by MRI and histology. Further analysis indicated a biallelic loss of GNAS in the tumor. CONCLUSIONS: This case provides important insights into the role of GNAS as a tumor suppressor and the emerging association between inactivating GNAS variants and the development of medulloblastoma. The case underscores the importance of careful neurological assessment and ongoing vigilance in children with known inactivating GNAS variants or associated phenotypes. Further work to establish genotype-phenotype correlations is needed to inform optimal management of these patients.


Asunto(s)
Neoplasias Cerebelosas , Cromograninas , Subunidades alfa de la Proteína de Unión al GTP Gs , Meduloblastoma , Osificación Heterotópica , Enfermedades Cutáneas Genéticas , Humanos , Subunidades alfa de la Proteína de Unión al GTP Gs/genética , Masculino , Cromograninas/genética , Meduloblastoma/genética , Meduloblastoma/patología , Osificación Heterotópica/genética , Osificación Heterotópica/patología , Enfermedades Cutáneas Genéticas/genética , Enfermedades Cutáneas Genéticas/patología , Enfermedades Cutáneas Genéticas/complicaciones , Lactante , Neoplasias Cerebelosas/genética , Neoplasias Cerebelosas/patología , Neoplasias Cerebelosas/complicaciones , Pronóstico , Enfermedades Óseas Metabólicas/genética , Enfermedades Óseas Metabólicas/patología , Mutación
10.
Clin Dermatol ; 41(3): 396-404, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37423265

RESUMEN

Annular and acral/facial dyskeratotic paraneoplastic disorders are inflammatory dermatoses that occur in association with distant cancers but are not precursors, extensions, or metastases of them. There are four classical entities under this rubric: two gyrate entities, erythema annulare centrifugum and erythema gyratum repens, and two acral/facial dyskeratotic entities, acrokeratosis paraneoplastic (Bazex syndrome) and tripe palms. Each of these entities may also occur in association with another etiopathogenesis and may present either as a classical entity or as a barely recognizable disease. We discuss these entities, their associated causes, and their differential diagnoses in turn.


Asunto(s)
Síndromes Paraneoplásicos , Enfermedades Cutáneas Genéticas , Neoplasias Cutáneas , Humanos , Eritema/etiología , Piel/patología , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/patología , Enfermedades Cutáneas Genéticas/patología , Síndromes Paraneoplásicos/etiología , Síndromes Paraneoplásicos/diagnóstico
11.
Exp Dermatol ; 32(9): 1334-1343, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37353900

RESUMEN

Dyschromatosis universalis hereditaria (DUH) is characterized by diffuse symmetrically distributed hypopigmented macules mixed with hyperpigmentation. DUH is divided into three types by Online Mendelian inheritance in man (OMIM) that is, DUH1 (OMIM 127500), DUH2 (OMIM 612715) and DUH3 (OMIM 615402) according to the different linkage regions. Although each condition possesses corresponding phenotypic characteristics and the prognosis for each is somewhat different, these disorders are highly overlapped and difficult to differentiate in the clinical setting. Our latest study reveals a novel DUH subtype that presents a mild phenotype of pigmentation anomalies and is named PER3rs772027021 SNP related DUH or DUH4 by us, which make the DUH subtype can be further retyped. Heterozygous distribution or mosaic-like distribution of melanin is a newly discovered pathological features that is uniquely demonstrated in the affected layers of DUH1 and DUH4 patients. In this review, DUH is further divided into four subtypes according the causative genes and their mutational sites, and the mutation regions described in the previous reports. To make an accurate diagnosis, we suggest that Sanger sequencing or the target region sequencing (TRS) to the candidate causative genes related melanogenesis may be the most effective and convenient method of clinical diagnosis or/and prenatal diagnosis for DUH and DUH-like patients. More importantly, heterozygous distribution or mosaic-like distribution of melanin can be utilized for differential diagnosis of DUH. We also investigate the underlying molecular mechanism to form mosaic-like melanin in the affected layers of hyper- and/or hypo-pigmented macules from DUH1 and DUH4 patients. This review provides a molecular and pathological delineation of four types of DUH and aims to establish a concise diagnostic strategy to allow clinical dermatologists to make an accurate diagnosis.


Asunto(s)
Hiperpigmentación , Enfermedades Cutáneas Genéticas , Humanos , Patología Molecular , Melaninas/genética , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/genética , Enfermedades Cutáneas Genéticas/patología , Hiperpigmentación/diagnóstico , Hiperpigmentación/genética , Linaje
12.
J Dermatol Sci ; 110(2): 53-60, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37100691

RESUMEN

BACKGROUND: Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disease characterized by aberrant keratinocyte differentiation, epidermal hyperproliferation, and amyloid deposits. Previously, we demonstrated OSMR loss-function mutants enhanced basal keratinocyte differentiation through the OSMR/STAT5/KLF7 signaling in PLCA patients. OBJECTIVE: To investigate the underlying mechanisms involved in basal keratinocyte proliferation in PLCA patients that remain unclear. METHODS: Patients with pathologically confirmed PLCA visiting the dermatologic outpatient clinic were involved in the study. Laser capture microdissection and mass spectrometry analysis, gene-edited mice, 3D human epidermis culture, flow cytometry, western blot, qRT-PCR and RNA sequencing were used to explore the underlying molecular mechanisms. RESULTS: In this study, we found that AHNAK peptide fragments were enriched in the lesions of PLCA patients, as detected by laser capture microdissection and mass spectrometry analysis. The upregulated expression of AHNAK was further confirmed using immunohistochemical staining. qRT-PCR and flow cytometry revealed that pre-treatment with OSM can inhibit AHNAK expression in HaCaT cells, NHEKs, and 3D human skin models, but OSMR knockout or OSMR mutations abolished this down-regulation trend. Similar results were obtained in wild-type and OSMR knockout mice. More importantly, EdU incorporation and FACS assays demonstrated the knockdown of AHNAK could induce G1 phase cell cycle arrest and inhibit keratinocyte proliferation. Furthermore, RNA sequencing revealed that AHNAK knockdown regulated keratinocyte differentiation. CONCLUSION: Taken together, these data indicated that the elevated expression of AHNAK by OSMR mutations led to hyperproliferation and overdifferentiation of keratinocytes, and the discovered mechanism might provide insights into potential therapeutic targets for PLCA.


Asunto(s)
Amiloidosis Familiar , Enfermedades Cutáneas Genéticas , Humanos , Animales , Ratones , Enfermedades Cutáneas Genéticas/patología , Piel/patología , Amiloidosis Familiar/genética , Queratinocitos/metabolismo , Factores de Transcripción de Tipo Kruppel/metabolismo , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Proteínas de Neoplasias/metabolismo , Oncostatina M/farmacología , Subunidad beta del Receptor de Oncostatina M/genética
13.
Pediatr Dermatol ; 40(4): 681-687, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36599189

RESUMEN

Annular erythema of infancy is a rare, benign disease characterized by enlarging annular patches and plaques that resolve spontaneously. Histopathology typically demonstrates a perivascular mixed lymphohistiocytic infiltrate with increased eosinophils. We present two cases of annular erythema of infancy, at ages 2-4 weeks, and review the literature on annular erythema of infancy. It is important to differentiate this distinct, benign disease from serious autoimmune or infectious processes, such as neonatal lupus erythematosus and syphilis, which may present with similar annular lesions in infancy.


Asunto(s)
Eosinofilia , Lupus Eritematoso Sistémico , Enfermedades Cutáneas Genéticas , Recién Nacido , Humanos , Lactante , Eritema/diagnóstico , Eritema/patología , Enfermedades Cutáneas Genéticas/patología , Eosinofilia/patología , Enfermedades Raras
15.
Am J Med Genet A ; 191(3): 899-901, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36448706

RESUMEN

Sarcoidosis is a chronic granulomatous disorder affecting the lungs, skin, and many other organs. Twin studies suggest that genetic factors account, to a large degree, for the etiology of the disorder. Hence, theoretically, we could postulate that the phenomenon of superimposed mosaicism in the form of a pronounced segmental involvement, overlaying the disseminated non-segmental lesions, should also occur in sarcoidosis. Indeed, one case suggesting superimposed mosaicism in cutaneous sarcoidosis was found in the literature and is reassessed here.


Asunto(s)
Sarcoidosis , Enfermedades Cutáneas Genéticas , Enfermedades de la Piel , Humanos , Mosaicismo , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/genética , Enfermedades Cutáneas Genéticas/patología , Piel/patología , Sarcoidosis/diagnóstico , Sarcoidosis/genética , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/genética , Enfermedades de la Piel/patología
16.
BMC Endocr Disord ; 22(1): 70, 2022 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-35296306

RESUMEN

BACKGROUND: The GNAS gene on chromosome 20q13.3, encodes the alpha-subunit of the stimulatory G protein, which is expressed in most tissues and regulated through reciprocal genomic imprinting. Disorders of GNAS inactivation produce several different clinical phenotypes including pseudohypoparathyroidism (PHP), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). The clinical and biochemical characteristics overlap of PHP subtypes and other related disorders presents challenges for differential diagnosis. METHODS: We enrolled a total of 11 Chinese children with PHP in our study and analyzed their clinical characteristics, laboratory results, and genetic mutations. RESULTS: Among these 11 patients, nine of them (9/11) presented with resistance to parathyroid hormone (PTH); and nine (9/11) presented with an Albright's hereditary osteodystrophy (AHO) phenotype. GNAS abnormalities were detected in all 11 patients, including nine cases with GNAS gene variations and two cases with GNAS methylation defects. These GNAS variations included an intronic mutation (c.212 + 3_212 + 6delAAGT), three missense mutations (c.314C > T, c.308 T > C, c.1123G > T), two deletion mutations (c.565_568delGACT*2, c.74delA), and two splicing mutations (c.721 + 1G > A, c.432 + 1G > A). Three of these mutations, namely, c.314C > T, c.1123G > T, and c.721 + 1G > A, were found to be novel. This data was then used to assign a GNAS subtype to each of these patients with six cases diagnosed as PHP1a, two cases as PHP1b, one as PPHP, and two as POH. CONCLUSIONS: Evaluating patients with PTH resistance and AHO phenotype improved the genetic diagnosis of GNAS mutations significantly. In addition, our results suggest that when GNAS gene sequencing is negative, GNAS methylation study should be performed. Early genetic detection is required for the differential diagnosis of GNAS disorders and is critical to the clinician's ability to distinguish between heterotopic ossification in the POH and AHO phenotype.


Asunto(s)
Enfermedades Óseas Metabólicas , Cromograninas/genética , Subunidades alfa de la Proteína de Unión al GTP Gs/genética , Osificación Heterotópica , Seudohipoparatiroidismo , Enfermedades Cutáneas Genéticas , Adolescente , Enfermedades Óseas Metabólicas/diagnóstico , Enfermedades Óseas Metabólicas/genética , Enfermedades Óseas Metabólicas/patología , Niño , Preescolar , China , Femenino , Humanos , Lactante , Masculino , Osificación Heterotópica/diagnóstico , Osificación Heterotópica/genética , Osificación Heterotópica/patología , Seudohipoparatiroidismo/diagnóstico , Seudohipoparatiroidismo/genética , Seudohipoparatiroidismo/patología , Seudoseudohipoparatiroidismo/diagnóstico , Seudoseudohipoparatiroidismo/genética , Seudoseudohipoparatiroidismo/patología , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/genética , Enfermedades Cutáneas Genéticas/patología
17.
Eur J Ophthalmol ; 32(5): NP1-NP4, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34308677

RESUMEN

Ligneous conjunctivitis is a rare form of chronic, recurrent conjunctivitis characterized by wood-like, fibrinous pseudomembranes, which may be associated with systemic disease manifestations. It has been associated with congenital plasminogen (PLG) deficiency that is inherited with an autosomal recessive pattern due to mutations in the PLG gene and a variety of other genes, leading to disturbed wound healing. In this case report, we present the clinical, laboratory, and histopathological findings of a 36-year-old female patient who presented at the ophthalmology department with complaints of redness, irritation for the previous few weeks, and appearance of membranous lesions mainly on the tarsal conjunctivae. During biomicroscopic examination we found thick, yellowish-white pseudomembranes, and conjunctival proliferation with ligneous induration on the conjunctiva, located on the upper eyelids. Histopathological evaluations showed up ligneous conjunctivitis and laboratory evaluation confirmed a severe plasminogen deficiency (PLG < 2%). The patient was treated with topical fresh frozen plasma (FFP), topical steroids, heparin eye drops, and artificial tear drops daily, without systemic therapy.


Asunto(s)
Conjuntivitis , Enfermedades Cutáneas Genéticas , Adulto , Trastornos de las Proteínas de Coagulación , Conjuntiva/patología , Conjuntivitis/diagnóstico , Conjuntivitis/tratamiento farmacológico , Conjuntivitis/etiología , Femenino , Humanos , Plasminógeno/deficiencia , Plasminógeno/genética , Enfermedades Cutáneas Genéticas/complicaciones , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/patología
18.
Dermatology ; 238(3): 579-586, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34525472

RESUMEN

BACKGROUND: Primary localized cutaneous amyloidosis (PLCA) is defined by the deposition of amyloid protein in the skin without systemic involvement. There are four subtypes of PLCA: lichen amyloidosis (LA), macular amyloidosis (MA), biphasic amyloidosis (BA), and nodular amyloidosis (NA). PLCA occurs most frequently in Latin Americans and Asians. Treatment is not standardized. OBJECTIVES: To identify subtypes, demographic and clinical features and treatment efficacy in patients with histopathologically confirmed PLCA. MATERIALS AND METHODS: Data of PLCA patients were extracted from the electronic hospital database and included if diagnosis of PLCA was histopathologically confirmed and if sufficient information regarding treatment and follow-up was available. The evaluation of the treatment efficacy was based on a novel score to assess the reduction of itch and skin lesions. RESULTS: In this retrospective, monocentric study, 37 cases of PLCA diagnosed between 2000 and 2020 were included (21 females) with a mean age of 52 years. LA was the most frequent subtype found in 21 patients (56.8%), followed by MA in 10 patients (28%) and BA in 6 patients (16.2%). No cases of NA were included. 22 patients (59.4%) had skin phototype II or III. Regarding treatment, a combination of UVA1 phototherapy with high-potency topical corticosteroids seemed to show the highest efficacy with complete clearance of symptoms in 4 patients (10.8%). A substantial improvement of symptoms was found in 5 patients (12.7%) treated with high-potency topical corticosteroids alone or in combination either with UVA1 or bath PUVA or monotherapy with UVA1 phototherapy or capsaicin (0.075%) cream. Low-/medium-potency topical corticosteroids alone or in combination with UVBnb (311 nm) phototherapy showed a lower efficacy. CONCLUSION: Our data show that PCLA is a rare disease in central Europe but can also be expected in a predominantly Caucasian population. The best treatment response was achieved with a combination of UVA1 phototherapy and high-potency topical corticosteroids.


Asunto(s)
Amiloidosis , Fármacos Dermatológicos , Enfermedades Cutáneas Genéticas , Corticoesteroides/uso terapéutico , Amiloidosis/patología , Amiloidosis Familiar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Genéticas/patología , Enfermedades Cutáneas Genéticas/terapia , Suiza , Centros de Atención Terciaria
19.
Am J Dermatopathol ; 44(1): 28-32, 2022 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-34889811

RESUMEN

ABSTRACT: Cutaneous amyloidosis (CA) is defined by the accumulation of amyloid in the dermis; it might be primary or secondary. The diagnosis is based on histopathological findings with the demonstration of amyloid deposits, confirmed by Congo red stain under the polarized light. Studies on other diagnostic markers are ongoing in the literature. The aim of this study was to demonstrate the utility of C4d staining in the recognition of amyloid in CA and using it as an alternative or substitute marker for the diagnosis. In this retrospective study, 199 skin biopsies with a clinical provisional diagnosis of CA were analyzed, the Congo red stain was performed, and, in a subgroup (n = 97) with histopathological findings probably for CA, C4d immunohistochemistry was assessed. Forty-eight cases of CA were detected. Congo red birefringence was positive in all cases, whereas in 14 cases, it was faded. In these 14 cases, the diagnosis of CA was made by means of Congo red fluorescence and Thioflavin T because the histopathological findings were highly suggestive for CA. All CA cases were positive with C4d, and in 12 of the 49 inflammatory dermatoses, C4d was positive. The interpretation of C4d immunohistochemistry can be performed more easily and rapidly than Congo red evaluation. The sensitivity and specificity of C4d were 100% and 75.5%, respectively. In our experience, C4d staining was a useful method for detecting amyloid deposits in CA. Although Congo red staining is the gold standard for amyloid detection, we propose C4d immunohistochemistry as a routine screening method or hybrid transition while further investigations are completed.


Asunto(s)
Amiloidosis Familiar/patología , Complemento C4b/análisis , Fragmentos de Péptidos/análisis , Enfermedades Cutáneas Genéticas/patología , Adulto , Anciano , Anciano de 80 o más Años , Amiloidosis Familiar/diagnóstico , Biomarcadores/análisis , Colorantes/uso terapéutico , Rojo Congo/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Enfermedades Cutáneas Genéticas/diagnóstico
20.
Am J Dermatopathol ; 44(3): e29-e32, 2022 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-34816802

RESUMEN

ABSTRACT: Dowling-Degos Disease (DDD) is a rare and disfiguring autosomal dominant genodermatosis characterized by reticulate hyperpigmented macules or follicular comedone-like papules in the intertriginous areas that typically presents in the third or fourth decade of life. It is a progressive disease that is often treatment-resistant. Although its association with hidradenitis suppurativa has been well described, DDD has also been less commonly reported in conjunction with other dermatologic diseases with unknown etiologic associations. Herein, we present a case of DDD with associated epidermal inclusion cysts and conduct a literature review of dermatologic conditions reported in association with DDD.


Asunto(s)
Quiste Epidérmico/patología , Hiperpigmentación/patología , Enfermedades Cutáneas Genéticas/patología , Enfermedades Cutáneas Papuloescamosas/patología , Adulto , Quiste Epidérmico/diagnóstico , Humanos , Hiperpigmentación/diagnóstico , Masculino , Enfermedades Cutáneas Genéticas/diagnóstico , Enfermedades Cutáneas Papuloescamosas/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...